How big is Upexi, Inc.?

As of Jun 18, Upexi, Inc. has a market capitalization of 363.61 million, with net sales of 16.75 million and a net profit of -11.15 million over the latest four quarters. As of Jun 24, the company reported shareholder's funds of 6.52 million and total assets of 23.51 million.

Market Cap: As of Jun 18, Upexi, Inc. has a market capitalization of 363.61 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Upexi, Inc. reported net sales of 16.75 million and a net profit of -11.15 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 6.52 million and total assets of 23.51 million.

What does Upexi, Inc. do?

Upexi, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $4 million as of March 2025. Key metrics include a market cap of $363.61 million, a debt-to-equity ratio of 3.90, and a return on equity of -616.52%.

Overview: <BR>Upexi, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 363.61 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.90 <BR>Return on Equity: -616.52% <BR>Price to Book: 196.47<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Upexi, Inc.?

Is Upexi, Inc. overvalued or undervalued?

As of September 28, 2022, Upexi, Inc. is considered risky due to its extreme P/B ratio of 229.66, negative EV to EBITDA of -44.95, and a concerning ROE of -616.52%, indicating overvaluation and financial challenges compared to peers, despite a strong year-to-date return of 94.3%.

As of 28 September 2022, the valuation grade for Upexi, Inc. moved from attractive to risky, indicating a shift in perception regarding its financial health. Based on the available metrics, Upexi appears to be overvalued, particularly given its extreme P/B ratio of 229.66 and negative EV to EBITDA of -44.95, which suggest significant challenges in generating earnings relative to its valuation. Additionally, the company's ROE stands at a concerning -616.52%, further highlighting its struggles.<BR><BR>In comparison to its peers, Upexi's valuation ratios are notably unfavorable; for instance, Chromadex Corp. has a P/E of 39.82, while LifeVantage Corp. shows a more reasonable P/E of 14.81. This stark contrast underscores Upexi's risky standing in the market. Despite a strong year-to-date return of 94.3% compared to the S&P 500's 12.22%, the long-term performance reveals a troubling trend, with a 3-year return of -91.48%, suggesting that the recent gains may not be sustainable.

Is Upexi, Inc. technically bullish or bearish?

As of September 12, 2025, Upexi, Inc. shows a mildly bullish trend, supported by a bullish daily moving average and monthly MACD, while outperforming the S&P 500 with a year-to-date return of 94.3% compared to 12.22%.

As of 12 September 2025, the technical trend for Upexi, Inc. has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by a bullish daily moving average and a monthly MACD that is mildly bullish, despite the weekly MACD and KST being mildly bearish. The Bollinger Bands also reflect a mildly bullish trend on a monthly basis. <BR><BR>In terms of performance, Upexi has significantly outperformed the S&P 500 year-to-date with a return of 94.3% compared to the S&P's 12.22%. However, over the past year, Upexi's return of 62.38% still shows strong performance relative to the S&P 500's 17.14%.